Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey

The evolving epidemiology and treatment landscape of COVID-19 necessitates research into potential drug-drug interactions (pDDIs) from the use of new treatments for COVID-19, particularly those that contain ritonavir, a potent inhibitor of the cytochrome P350 3A4 (CYP3A4) metabolic pathway. In this...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2023-05, Vol.45 (5), p.390-399.e4
Hauptverfasser:	Igho-Osagie, Ebuwa, Brzozowski, Kaylen, Jin, Harry, Brown, Jeffrey, Williams, Marissa Grifasi, Puenpatom, Amy
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adult AIDS Antimicrobial agents Antiretroviral drugs Antiviral drugs Chronic conditions Chronic illnesses Comorbidity Contraindications Coronaviruses COVID-19 COVID-19 - complications COVID-19 - epidemiology COVID-19 Drug Treatment Cytochrome Cytochrome P-450 CYP3A Cytochromes Data collection Dementia Diabetes mellitus Drug interaction Drug Interactions Drugs Epidemiology HIV HIV Infections - drug therapy Human immunodeficiency virus Humans Kidney diseases Medical laboratories Metabolic pathways NHANES nirmatrelvir/ritonavir Nutrition Nutrition Surveys Older people Pandemics Polypharmacy Population studies Prevalence Risk factors Ritonavir Ritonavir - therapeutic use Sickle cell disease Statins Surveys Transplants & implants United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!